Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy

Charles F Zorumski, Peter Nagele, Steven Mennerick, Charles R Conway, Charles F Zorumski, Peter Nagele, Steven Mennerick, Charles R Conway

Abstract

Major depressive disorder (MDD) remains a huge personal and societal encumbrance. Particularly burdensome is a virulent subtype of MDD, treatment resistant major depression (TMRD), which afflicts 15-30% of MDD patients. There has been recent interest in N-methyl-d-aspartate receptors (NMDARs) as targets for treatment of MDD and perhaps TMRD. To date, most pre-clinical and clinical studies have focused on ketamine, although psychotomimetic and other side effects may limit ketamine's utility. These considerations prompted a recent promising pilot clinical trial of nitrous oxide, an NMDAR antagonist that acts through a mechanism distinct from that of ketamine, in patients with severe TRMD. In this paper, we review the clinical picture of TRMD as a subtype of MDD, the evolution of ketamine as a fast-acting antidepressant, and clinical and basic science studies supporting the possible use of nitrous oxide as a rapid antidepressant.

Keywords: NMDA receptors; antidepressant; hippocampus; ketamine; metaplasticity; suicide.

Figures

Figure 1
Figure 1
The scheme lists symptoms of depression according to changes in brain networks underlying emotion, motivation and cognition. Sleep disturbances may reflect homeostatic corrective efforts.
Figure 2
Figure 2
The graph shows the age of onset of MDD in the 79 patients evaluated in the TRMD clinic. The bars show the mean age of onset of MDD in these subjects according to family history including family members with MDD and bipolar disorder (BP). This figure has been adapted and modified from data presented in Ref. (25).
Figure 3
Figure 3
The graph shows the number of antidepressant trials documented in 79 patients evaluated in the TRMD clinic. Based on chart review and clinical interview, all trials listed in this graph had adequate dose and duration of antidepressant treatment.
Figure 4
Figure 4
The list includes various effects of nitrous oxide that could contribute to antidepressant and other CNS effects. Supporting studies are described in the text.

References

    1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA (2003) 289:3095–105.10.1001/jama.289.23.3095
    1. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 310:591–608.10.1001/jama.2013.13805
    1. Pirraglia PA, Rosen AB, Hermann RC, Olchanski NV, Neumann P. Cost-utility analysis of depression management: a systematic review. Am J Psychiatry (2004) 161:2155–62.10.1176/appi.ajp.161.12.2155
    1. Benton T, Staab J, Evans DL. Medical co-morbidity in depressive disorders. Ann Clin Psychiatry (2007) 19:289–303.10.1080/10401230701653542
    1. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet (2009) 373:746–58.10.1016/S0140-6736(09)60046-5
    1. Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv (2014) 65:977–87.10.1176/appi.ps.201300059
    1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 47:351–4.10.1016/S0006-3223(99)00230-9
    1. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther (2009) 123:143–50.10.1016/j.pharmthera.2009.02.010
    1. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry (1994) 51:199–214.10.1001/archpsyc.1994.03950030035004
    1. Mennerick S, Jevtovic-Todorovic V, Todorovic SM, Shen W, Olney JW, Zorumski CF. Effect of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures. J Neurosci (1998) 18:9716–26.
    1. Nagele P, Duma A, Kopec M, Gebara MA, Parsoei A, Walker M, et al. Nitrous oxide for treatment-resistant depression: a proof-of-concept trial. Biol Psychiatry (2015) 78:10–8.10.1016/j.biopsych.2014.11.016
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth ed Arlington, VA: American Psychiatric Association Press; (2013).
    1. Zorumski CF, Rubin EH. Psychiatry and Clinical Neuroscience: A Primer. New York, NY: Oxford University Press; (2011).
    1. Woodruff RA, Goodwin DW, Guze SB. Psychiatric Diagnosis. New York, NY: Oxford University Press; (1974).
    1. Rush AJ. STAR*D: what have we learned? Am J Psychiatry (2007) 164:201–4.10.1176/ajp.2007.164.2.201
    1. Eaton WW, Anthony JC, Gallo J, Cai G, Tien A, Romanoski A, et al. Natural history of diagnostic interview schedule/DSM-IV major depression. The Baltimore epidemiologic catchment area follow-up. Arch Gen Psychiatry (1997) 54:993–9.10.1001/archpsyc.1997.01830230023003
    1. Dunner DL, Rush AJ, Russell JM, Burke M, Woodard S, Wingard P, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry (2006) 67:688–95.10.4088/JCP.v67n0501
    1. Culpepper L, Muskin PR, Stahl SM. Major depressive disorder: understanding the significance of residual symptoms and balancing efficacy with tolerability. Am J Med (2015) 128:S1–15.10.1016/j.amjmed.2015.07.001
    1. McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord (2014) 156:1–7.10.1016/j.jad.2013.10.043
    1. Fagiolini A, Kupfer DJ. Is treatment resistant-depression a unique subtype of depression? Biol Psychiatry (2003) 53:6400–8.10.1016/S0006-3223(02)01670-0
    1. Trevino K, McClintock SM, McDonald-Fischer N, Vora A, Husain MM. Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry (2014) 26:222–32.
    1. Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry (1997) 58(Suppl 13):23–9.
    1. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry (2003) 53:649–59.10.1016/S0006-3223(03)00231-2
    1. Fekadu A, Wooderson SC, Markopoulou K, Cleare AJ. The Maudsley staging method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. J Clin Psychiatry (2009) 70:952–7.10.4088/JCP.08m04728
    1. Conway CR, Gebara MA, Walker MC, Lessov-Schlaggar CN, Janski AM, Chibnall JT, et al. Clinical characteristics and management of treatment-resistant depression. J Clin Psychiatry (2015) 62(Suppl 16):18–25.10.4088/JCP.14l09462
    1. George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, et al. A one year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry (2005) 58:364–73.10.1016/j.biopsych.2005.07.028
    1. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry (2005) 58:347–54.10.1016/j.biopsych.2005.05.025
    1. Gershon ES, Hamovit J, Guroff JJ, Dibble E, Leckman JF, Sceery W, et al. A family study of schizoaffective, bipolar I, bipolar II, unipolar, and normal control probands. Arch Gen Psychiatry (1982) 39:1157–67.10.1001/archpsyc.1982.04290100031006
    1. Akiskal HS, Benazzi F. Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II? J Affect Disord (2005) 84:209–17.10.1016/j.jad.2004.05.004
    1. Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Keller M, et al. Switching from unipolar to bipolar II – an 11-year prospective-study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry (1995) 52:114–23.10.1001/archpsyc.1995.03950140032004
    1. Benazzi F, Akiskal HS. How best to identify a bipolar-related subtype among major depressive patients without spontaneous hypomania: superiority of age at onset criterion over recurrence and polarity? J Affect Disord (2008) 107:77–88.10.1016/j.jad.2007.07.032
    1. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry (1998) 59:279–88.10.4088/JCP.v59n0602
    1. Correa R, Akiskal H, Gilmer W, Nierenberg AA, Trivedi M, Zisook S. Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? J Affect Disord (2010) 127:10–8.10.1016/j.jad.2010.06.036
    1. Amital D, Fostick L, Silberman A, Beckman M, Spivak B. Serious life events among resistant and non-resistant MDD patients. J Affect Disord (2008) 110:260–4.10.1016/j.jad.2008.01.006
    1. Sagud M, Mihaljevic-Peles A, Uzun S, Cusa BV, Kozumplik O, Kudlek-Mikulic S, et al. The lack of association between components of metabolic syndrome and treatment resistance in depression. Psychopharmacology (Berl) (2013) 230:15–21.10.1007/s00213-013-3085-x
    1. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 63:856–64.10.1001/archpsyc.63.8.856
    1. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry (1995) 52:998–1007.10.1001/archpsyc.1995.03950240016004
    1. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry (2015) 172:950–66.10.1176/appi.ajp.2015.15040465
    1. Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev (2015) 9:CD011612.10.1002/1465/14651858
    1. Rasmussen KG, LIneberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol (2013) 27:444–50.10.1177/0269881113478283
    1. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistent major depression. Biol Psychiatry (2013) 74:250–6.10.1016/j.biopsych/2012.06.022
    1. Dahan A, Olofsen E, Sigtermans M, Noppers I, Niesters M, Aarts L, et al. Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain (2011) 15:258–67.10.1016/j.ejpain.2010.06.016
    1. Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol (2014) 77:357–67.10.1111/bcp.12094
    1. Lapidus KAB, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry (2014) 76:970–6.10.1016/j.biopsych.2014.03.026
    1. Luckenbaugh DA, Ibrahim L, Brutsche N, Franco-Chaves J, Mathews D, Marquardt CA, et al. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord (2012) 14:880–7.10.1111/bdi.12003
    1. Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry (2014) 71:681–8.10.1001/jamapsychiatry.2014.62
    1. Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res (2014) 58:161–6.10.1016/j.jpsychires.2014.07.027
    1. Reinstatler L, Youssef NA. Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. Drugs R D (2015) 15:37–43.10.1007/s40268-015-0081-0
    1. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji H, Zarate CA. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2009) 65:181–4.10.1016/j.biopsych.2008.09.029
    1. Krystal JH, Petrakis IL, Limoncelli D, Webb E, Gueorgueva R, D’Souza DC, et al. Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology (2003) 28:2020–8.10.1038/sj.npp.1300252
    1. Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, et al. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry (1998) 55:354–60.10.1001/archpsyc.55.4.354
    1. Petrakis IL, Limoncelli D, Gueorguieva R, Jatlow P, Boutros NN, Trevisan L, et al. Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry (2004) 161:1776–82.10.1176/ajp.161.10.1776
    1. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol (2006) 26:365–84.10.1007/s10571-006-9062-8
    1. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol (1990) 185:1–10.10.1016/0014-2999(90)90204-J
    1. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation and function. Pharmacol Rev (2010) 62:405–96.10.1124/pr.109.002451
    1. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci (2013) 14:383–400.10.1038/nrn3504
    1. Paul SM, Doherty JJ, Robichaud AJ, Belfort GM, Chow BY, Hammond RS, et al. The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J Neurosci (2013) 33:17290–300.10.1523/JNEUROSCI.2619-13.2013
    1. Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron (2004) 44:5–21.10.1016/j.neuron.2004.09.012
    1. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ­ketamine and phencyclidine, selectively reduce excitation of central ­mammalian neurons by N-methyl-aspartate. Br J Pharmacol (1983) 79:565–75.10.1111/j.1476-5381.1983.tb11031.x
    1. Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol (2015) 172:4254–76.10.1111/bph.13222
    1. Huettner JE, Bean BP. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc Natl Acad Sci U S A (1988) 85:1307–11.10.1073/pnas.85.4.1307
    1. MacDonald JF, Miljkovic Z, Pennefather P. Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. J Neurophysiol (1987) 58:251–66.
    1. Kotermanski SE, Wood JT, Johnson JW. Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J Physiol (2009) 587:4589–604.10.1113/jphysiol.2009.176297
    1. Kotermanski SE, Johnson JW. Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer’s drug memantine. J Neurosci (2009) 29:2774–9.10.1523/JNEUROSCI.3703-08.2009
    1. Hartvig P, Valtysson J, Lindner K-J, Kristensen J, Karlsten R, Gustafsson LL, et al. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther (1995) 58:165–73.10.1016/0009-9236(95)90194-9
    1. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacolology (1999) 20:106–18.10.1016/S0893-133X(98)00067-0
    1. Zhao X, Venkata SLV, Moaddel R, Luckenbaugh DA, Brutsche NE, Ibrahim L, et al. Simultaneous population pharmacokinetic modeling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol (2012) 74:304–14.10.1111/j.1365-2125.2012.04198.x
    1. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci (2007) 24:11496–500.10.1523/JNEUROSCI.2213-07.2007
    1. Emnett CM, Eisenman LN, Mohan J, Taylor AA, Doherty JJ, Paul SM, et al. Interaction between positive allosteric modulators and trapping blockers of the NMDA receptor channel. Br J Pharmacol (2015) 172:1333–47.10.1111/bph.13007
    1. Emnett CM, Eisenman LN, Taylor AM, Izumi Y, Zorumski CF, Mennerick S. Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine. Mol Pharmacol (2013) 84:935–47.10.1124/mol.113.089334
    1. Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (2010) 329:959–64.10.1126/science.1190287
    1. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P-F, et al. NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature (2011) 475:91–5.10.1038/nature10130
    1. Fuchikami M, Thomas A, Liu R, Wohleb ES, Land BB, DiLeone RJ, et al. Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions. Proc Natl Acad Sci U S A (2015) 112:8106–11.10.1073/pnas.1414728112
    1. Dwyer JM, Duman RS. Activation of mammalian target of rapamycin and synaptogenesis: role of the actions of rapid-acting antidepressants. Biol Psychiatry (2013) 73:1189–98.10.1016/j.biopsych.2012.11.011
    1. Dwyer JM, Maldonado-Aviles JG, Lepack AE, DiLeone RJ, Duman RS. Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior. Proc Natl Acad Sci U S A (2015) 112:6188–93.10.1073/pnas.1505289112
    1. Nosyreva E, Szabla K, Autry AE, Ryazanov AG, Monteggia LM, Kavalali E. Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci (2013) 33:6990–7002.10.1523/JNEUROSCI.4998-12.2013
    1. Miller OH, Yang Y, Wang C-C, Hargroder E, Zhang Y, Delpire E, et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. eLIFE (2014) 10:e03581.10.7554/eLife.03581
    1. Izumi Y, Zorumski CF. Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function. Neuropharmacology (2014) 86:273–81.10.1016/j.neuropharm.2014.08.002
    1. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol (2008) 28:631–7.10.1097/JCP.0b013e31818a6cea
    1. Jimenez-Sanchez L, Campa L, Auberson YP, Adell A. The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression. Neuropsychopharmacology (2014) 39:2673–80.10.1038/npp.2014.123
    1. Sheline YI, Price JL, Yan Z, Mintun MA. Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci U S A (2010) 107:11020–5.10.1073/pnas.1000446107
    1. Scheidegger M, Walter M, Lehmann M, Metzger C, Grimm S, Boeker H, et al. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One (2012) 7:e44799.10.1371/journal.pone.0044799
    1. Anticevic A, Corlett PR, Cole MW, Savic A, Gancsos M, Tang Y, et al. N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia. Biol Psychiatry (2015) 77:569–80.10.1016/j.biopsych.2014.07.022
    1. Anticevic A, Gancsos M, Murray JD, Repovs G, Driesen NR, Ennis DJ, et al. NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci U S A (2012) 109:16720–5.10.1073/pnas.1208494109
    1. Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron (2013) 78:81–93.10.1016/j.neuron.2013.02.011
    1. Muthukumaraswamy SD, Shaw AD, Jackson LE, Hall J, Moran R, Saxena N. Evidence that subanesthetic doses of ketamine cause sustained disruptions of NMDA and AMPA-mediated frontoparietal connectivity in humans. J Neurosci (2015) 35:11694–706.10.1523/JNEUROSCI.0903-15.2015
    1. Ma L, Skoblenick KI, Seamans JK, Everling S. Ketamine-induced changes in the signal and noise rule of representation in working memory by lateral prefrontal neurons. J Neurosci (2015) 35:11612–22.10.1523/JNEUROSCI.1839-15.2015
    1. Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA, Charney DS. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol (2014) 54:119–39.10.1146/annurev-pharmtox-011613-135950
    1. Sanacora G, Smith MA, Pathak S, Su H-L, Boeijinga PH, McCarthy DJ, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry (2013) 19:978–85.10.1038/mp.2013.130
    1. Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol (2013) 16:501–6.10.1017/S1461145712000910
    1. Zarate CA, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 163:153–5.10.1176/appi.ajp.163.1.153
    1. Johnson JW, Glasgow NG, Povysheva NV. Recent insights into the mode of action of memantine and ketamine. Curr Opin Pharmacol (2015) 20:54–63.10.1016/j.coph.2014.11.006
    1. Gideons ES, Kavalali ET, Monteggia LM. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci U S A (2014) 111:8649–54.10.1073/pnas.1323920111
    1. Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology (2008) 109:707–22.10.1097/ALN.0b013e3181870a17
    1. Milne B. Nitrous oxide (laughing gas) inhalation as an alternative to electroconvulsive therapy. Med Hypotheses (2010) 74:780–1.10.1016/j.mehy.2009.11.021
    1. Jevtovic-Todorovic V, Todorovic SM, Mennerick S, Powell S, Dikranian K, Benshoff N, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med (1998) 4:460–3.10.1038/nm0498-460
    1. Nagashima K, Zorumski CF, Izumi Y. Nitrous oxide (laughing gas) facilitates excitability in rat hippocampal slices through γ-aminobutyric acid A receptor-mediated disinhibition. Anesthesiology (2005) 102:230–4.10.1097/00000542-200501000-00034
    1. Nosyreva E, Autry AE, Kavalali ET, Monteggia LM. Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade. Front Mol Neurosci (2014) 7:94.10.3389/fnmol.2014.00094
    1. Kuhlmann L, Foster BL, Liley DT. Modulation of functional EEG networks by the NMDA antagonist nitrous oxide. PLoS One (2013) 8:e56434.10.1371/journal.pone.0056434
    1. Foster BL, Liley DTJ. Effects of nitrous oxide sedation on resting electroencephalogram topography. Clin Neurophysiol (2013) 124:417–23.10.1016/j.clinph.2012.08.007
    1. Nagele P, Metz LB, Crowder CM. Nitrous oxide (N2O) requires the N-methyl-D-aspartate receptor for its action in Caenorhabditis elegans. Proc Natl Acad Sci U S A (2004) 101:8791–6.10.1073/pnas.0402825101
    1. Sato Y, Kobayashi E, Murayama T, Mishina M, Seo N. Effect of N-methyl-D-aspartate receptor epsilon 1 subunit gene disruption on the action of general anesthetics in mice. Anesthesiology (2005) 102:557–61.10.1097/00000542-200503000-00013
    1. Petrenko AB, Yamakura T, Kohno T, Sakimura K, Baba H. Reduced immobilizing properties of isoflurane and nitrous oxide in mutant mice lacking the N-methyl-D-aspartate receptor GluR (epsilon) 1 subunit are caused by the secondary effects of gene knockout. Anesth Analg (2010) 110:461–5.10.1213/ANE.0b013e3181c76e73
    1. Richardson KJ, Shelton KL. NMDA receptor blocker-like discriminative stimulus effects of nitrous oxide gas. J Pharmacol Exp Ther (2014) 352:156–65.10.1124/jpet.114.218057
    1. Todorovic SM, Jevtovic-Todorovic V, Mennerick S, Perez-Reyes E, Zorumski CF. Ca(v)3.2 channel is a molecular substrate for inhibition of T-type calcium currents in rat sensory neurons by nitrous oxide. Mol Pharmacol (2001) 60:603–10.
    1. Orestes P, Bojadzic D, Lee J, Leach E, Salajegheh R, Digruccio MR, et al. Free radical signaling underlies inhibition of Cav3.2 T-type calcium channels by nitrous oxide in the pain pathway. J Physiol (2011) 589:135–48.10.1113/jphysiol.2010.196220
    1. Bartels P, Behnke K, Michels G, Groner F, Schneider T, Henry M, et al. Structural and biophysical determinants of single Ca(v)3.1 and Ca(v)3.2 T-type calcium channel inhibition by N(2)O. Cell Calcium (2009) 46:293–302.10.1016/j.ceca.2009.09.002
    1. Todorovic SM, Jevtovic-Todorovic V, Meyenburg A, Mennerick S, Perez-Reyes E, Romano C, et al. Redox modulation of T-type calcium channels in rat peripheral nociceptors. Neuron (2001) 31:75–85.10.1016/S0896-6273(01)00338-5
    1. Choi Y-B, Lipton SA. Redox modulation of the NMDA receptor. Cell Mol Life Sci (2000) 57:1535–41.10.1007/PL00000638
    1. Gruss M, Bushell TJ, Bright DP, Lieb WR, Mathie A, Franks NP. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol (2004) 65:443–52.10.1124/mol.65.2.443
    1. Yamakura Y, Harris RA. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology (2000) 93:1095–101.10.1097/00000542-200010000-00034
    1. Daras C, Cantrill RC, Gillman MA. 3[H]-naloxone displacement: evidence for nitrous oxide as an opioid agonist. Eur J Pharmacol (1983) 89:177–8.10.1016/0014-2999(83)90626-X
    1. Ori C, Ford-Rice F, London ED. Effects of nitrous oxide and halothane on mu and kappa opioid receptors in guinea pig brain. Anesthesiology (1989) 70:541–4.10.1097/00000542-198903000-00027
    1. Fang F, Guo TZ, Davies MF, Maze M. Opiate receptor in the periaqueductal gray mediate analgesis effects of nitrous oxide in rats. Eur J Pharmacol (1997) 336:137–41.10.1016/S0014-2999(97)01219-3
    1. Ohashi Y, Guo TY, Orii R, Maze M, Fujinaga M. Brain stem opioidergic and GABAergic neurons mediate the antinociceptive effect of nitrous oxide in Fischer rats. Anesthesiology (2003) 99:947–54.10.1097/00000542-200310000-00030
    1. Sawamura S, Kingery WS, Davies MF, Agashe GS, Clark JD, Kobilka BK, et al. Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of 2B adrenoceptors. J Neurosci (2000) 20:9242–51.
    1. Orii R, Ohashi Y, Gui T, Nelson LE, Hashimoto T, Maze M, et al. Evidence for the involvement of spinal cord alpha 1 adrenoceptors in nitrous oxide-induced antinociceptive effects in Fischer rats. Anethesiology (2002) 97:1458–65.10.1097/00000542-200212000-00018
    1. Emmanouil DE, Quock R. Advances in understanding the actions of nitrous oxide. Anesth Prog (2007) 54:9–18.10.2344/0003-3006(2007)54[9:AIUTAO];2
    1. Caton PW, Tousman SA, Quock RM. Involvement of nitric oxide in nitrous oxide anxiolysis in the elevated plus maze. Pharmacol Biochem Behav (1994) 48:689–92.10.1016/0091-3057(94)90333-6
    1. Li S, Ohgami Y, Dai Y, Quock RM. Antagonism of nitrous oxide-induced anxiolytic-like behavior in the mouse light/dark exploration procedure by pharmacologic disruption of endogenous nitric oxide function. Psychopharmacology (2003) 166:366–72.
    1. Emmanouil DE, Papadopoulou-Daifoti Z, Hagihara PT, Quock DG, Quock RM. A study of the role of serotonin in the anxiolytic effect of nitrous oxide in rodents. Pharmacol Biochem Behav (2006) 84:313–20.10.1016/j.pbb.2006.05.016
    1. Czech DA, Quock RM. Nitrous oxide induces an anxiolytic-like effect in the conditioned defensive burying paradigm, which can be reversed with a benzodiazepine receptor blocker. Psychopharmacology (1993) 113:211–6.10.1007/BF02245699
    1. Emmanouil DE, Johnson CH, Quock RM. Nitrous oxide anxiolytic effect in mice in the elevated plus maze: mediation by benzodiazepine receptors. Psychopharmacology (1994) 115:167–72.10.1007/BF02244768
    1. Schreiber F, Wunderlin P, Udert KM, Wells GF. Nitric oxide and nitrous oxide turnover in natural and engineered microbial communities: biological pathways, chemical reactions and novel technologies. Front Microbiol (2012) 3:372.10.3389/fmicb.2012.00372
    1. Li S, Chung E, Quock RM. Role of cyclic GMP in nitrous oxide-induced anxiolytic-like behavior in the mouse light-dark exploration test. Behav Neurosci (2004) 118:648–52.10.1037/0735-7044.118.3.648
    1. Ranft A, Kurz J, Becker K, Dodt HU, Zieglgansberger W, Rammes G, et al. Nitrous oxide (N2O) pre- and postsynaptically attenuates NMDA receptor-mediated neurotransmission in the amygdala. Neuropharmacology (2007) 52:716–23.10.1016/j.neuropharm.2006.09.021
    1. Zarate CA, Machado-Vieira R. Potential pathways involved in the rapid antidepressant effects of nitrous oxide. Biol Psychiatry (2015) 78:2–14.10.1016/j.biopsych.2015.04.007
    1. Boultadakis A, Pitsikas N. Anesthetic ketamine impairs rats’ recall of previous information: the nitric oxide inhibitor N-nitro-L-arginine methylester antagonizes this ketamine-induced recognition memory defect. Anesthesiology (2011) 114:1345–53.10.1097/ALN.0b013e318219524e
    1. Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology (2015) 40:259–67.10.1038/npp.2014.261
    1. Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, et al. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. Eur J Pharmacol (2013) 698:228–34.10.1016/j.ejphar.2012.11.023
    1. Paul RK, Singh NS, Khadeer M, Moaddel R, Sanghvi M, Green CE, et al. (R,S)-ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function. Anesthesiology (2014) 121:149–59.10.1097/ALN.0000000000000285
    1. Zhou C, Douglas JE, Kumar NN, Shu S, Bayliss DA, Chen X. Forebrain HCN1 channels contribute to hypnotic actions of ketamine. Anesthesiology (2013) 118:785–95.10.1097/ALN.0b013e318287b7c8
    1. Zhang J-C, Li S-X, Hashimoto KR. (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav (2014) 116:137–41.10.1016/j.pbb.2013.11.033
    1. Franks NP, Dickinson R, de Sousa SLM, Hall AC, Lieb WR. How does xenon produce anesthesia? Nature (1998) 396:324.10.1038/24525
    1. Zorumski CF, Mennerick S, Izumi Y. Acute and chronic effects of ethanol on learning-related synaptic plasticity. Alcohol (2014) 48:1–17.10.1016/j.alcohol.2013.09.045
    1. Zorumski CF, Izumi Y. NMDA receptors and metaplasticity: mechanisms and possible roles in neuropsychiatric disorders. Neurosci Biobehav Rev (2012) 36:989–1000.10.1016/j.neubiorev.2011.12.011

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi